Glucagon-like peptide-1 receptor agonists should be considered for patients with type 2 diabetes; there is strong evidence for their reduction of major adverse cardiovascular events among patients with type 2 diabetes and CVD.15 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.